Caries Inhibitory Effect of Nano Silver and Tri Calcium Phosphate Varnishes Among Visually Impaired Children

Caries Inhibitory Effect of Nano Silver Varnish Versus Tri Calcium Phosphate Varnish Among Children With Visual Impairment

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06576960

Acronym

Prevention

Enrollment

Registered

2024-08-29

Start date

2022-10-11

Completion date

2023-04-13

Last updated

2024-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental Caries

Brief summary

Assessment of pH,streptococcus mutants count, lactobacillus count and immunoglobulin A among visually impaired children after nano silver varnish application it tri calcium phosphate phosphate varnish application

Detailed description

Sixty children will be randomly divided into three equal treatment groups, composed of 20 children each, according to the type of material used as follows: * Group I: children will receive oral health education and nano silver fluoride varnish. * Group II: children will receive oral health education and tri calcium phosphate varnish. * Group III: children will receive oral health education for all children ,Assessment of pH, streptococcus mutants count, lactobacillus count and immunoglobulin A will be assessed at baseline, one day , 3 months and 6 months after application

Interventions

DRUGNano silver fluoride varnish and tri calcium phosphate varnish

Fluoride varnishes

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

8 Years to 12 Years

Healthy volunteers

Inclusion criteria

Visually impaired children

Exclusion criteria

* uncooperative children or children not willing to participate in the study. * Children with systemic diseases * Children with bronchial asthma. * Children who were on antibiotic or medications that might affect oral flora or salivary flow taken within the previous 3 months * History of fluoride treatment in the past 3-4 weeks.

Design outcomes

Primary

Measure	Time frame	Description
Salivary PH	6 months	Salivary power of hydrogen at baseline, one month, 3months and six months after intervention
Salivary streptococcus mutants count	6months	Count of bacteria at baseline, one day, 3months and six months after intervention
Lactobacillus count	6 months	Count of bacteria at baseline, one day, 3months and six months after intervention
Immunoglobulin A	6months	Level of immunoglobulin A at saliva at baseline, one day, 3months and 6 months after intervention

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026